Minichmayr I, Plan E, Weber B, Ueckert S
Pharm Res. 2024; 42(1):123-135.
PMID: 39702686
PMC: 11785690.
DOI: 10.1007/s11095-024-03791-2.
Hudson D, Afzaal T, Bualbanat H, AlRamdan R, Howarth N, Parthasarathy P
Therap Adv Gastroenterol. 2024; 17:17562848241276334.
PMID: 39553445
PMC: 11565685.
DOI: 10.1177/17562848241276334.
Kraus N, Uschner F, Moeslein M, Schierwagen R, Gu W, Brol M
Cells. 2024; 13(20.
PMID: 39451225
PMC: 11505720.
DOI: 10.3390/cells13201707.
Omemeuda T, Sanada Y, Sakuma Y, Onishi Y, Sata N
Cureus. 2024; 16(9):e68789.
PMID: 39371903
PMC: 11456288.
DOI: 10.7759/cureus.68789.
Ratziu V, Francque S, Behling C, Cejvanovic V, Cortez-Pinto H, Iyer J
Hepatology. 2023; 80(1):173-185.
PMID: 38112484
PMC: 11185915.
DOI: 10.1097/HEP.0000000000000723.
Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level.
Gabriel-Medina P, Ferrer-Costa R, Ciudin A, Augustin S, Rivera-Esteban J, Pericas J
Intern Emerg Med. 2023; 19(3):745-756.
PMID: 37952070
PMC: 11039533.
DOI: 10.1007/s11739-023-03441-2.
EUS-guided percutaneous liver biopsy: A prospective randomized clinical trial.
Ali A, Nallapeta N, Yousaf M, Petroski G, Sharma N, Rao D
Endosc Ultrasound. 2023; 12(3):334-341.
PMID: 37693114
PMC: 10437149.
DOI: 10.1097/eus.0000000000000010.
The Link between NAFLD and Metabolic Syndrome.
Radu F, Potcovaru C, Salmen T, Filip P, Pop C, Fierbinteanu-Braticievici C
Diagnostics (Basel). 2023; 13(4).
PMID: 36832102
PMC: 9955701.
DOI: 10.3390/diagnostics13040614.
Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting.
Balitzer D, Tsai J, Gill R
Diagn Pathol. 2022; 17(1):65.
PMID: 35948927
PMC: 9367095.
DOI: 10.1186/s13000-022-01247-y.
Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis.
Kovalic A
J Clin Exp Hepatol. 2022; 12(4):1057-1068.
PMID: 35814516
PMC: 9257887.
DOI: 10.1016/j.jceh.2022.01.011.
Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients.
Wu C, Zhao Y, Zhang Y, Yang Y, Su W, Yang Y
J Adv Res. 2022; 37:197-208.
PMID: 35499044
PMC: 9039652.
DOI: 10.1016/j.jare.2021.07.011.
Non-alcoholic fatty liver disease: A patient guideline.
Francque S, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus J
JHEP Rep. 2021; 3(5):100322.
PMID: 34693236
PMC: 8514420.
DOI: 10.1016/j.jhepr.2021.100322.
A real-world study evaluating ultrasound-guided percutaneous non-targeted liver biopsy needle failures and pathology sample-quality assessment in both end-cut and side-notch needles.
Zhong J, Allard R, Hewitson D, Weston M, Hulson O, Burbidge S
Br J Radiol. 2021; 94(1125):20210475.
PMID: 34289324
PMC: 9327755.
DOI: 10.1259/bjr.20210475.
Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?.
Ipsen D, Lykkesfeldt J, Tveden-Nyborg P
Adv Nutr. 2020; 11(6):1696-1711.
PMID: 33191435
PMC: 7666900.
DOI: 10.1093/advances/nmaa081.
Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD.
Gawrieh S, Sethunath D, Cummings O, Kleiner D, Vuppalanchi R, Chalasani N
Ann Diagn Pathol. 2020; 47:151518.
PMID: 32531442
PMC: 8495470.
DOI: 10.1016/j.anndiagpath.2020.151518.
Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology.
Neuberger J, Patel J, Caldwell H, Davies S, Hebditch V, Hollywood C
Gut. 2020; 69(8):1382-1403.
PMID: 32467090
PMC: 7398479.
DOI: 10.1136/gutjnl-2020-321299.
Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives.
Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S
Int J Environ Res Public Health. 2019; 16(22).
PMID: 31703268
PMC: 6888162.
DOI: 10.3390/ijerph16224334.
Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution.
Haas J, Vonghia L, Mogilenko D, Verrijken A, Molendi-Coste O, Fleury S
Nat Metab. 2019; 1(6):604-614.
PMID: 31701087
PMC: 6837876.
DOI: 10.1038/s42255-019-0076-1.
An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.
Younossi Z, Karrar A, Pierobon M, Birerdinc A, Stepanova M, Abdelatif D
BMC Med. 2018; 16(1):170.
PMID: 30205811
PMC: 6134795.
DOI: 10.1186/s12916-018-1136-1.
Automated assessment of steatosis in murine fatty liver.
Sethunath D, Morusu S, Tuceryan M, Cummings O, Zhang H, Yin X
PLoS One. 2018; 13(5):e0197242.
PMID: 29746543
PMC: 5945052.
DOI: 10.1371/journal.pone.0197242.
